- Business Wire•18 days ago
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that on Thursday, May 4, 2017, after market close, the Company will release first quarter 2017 results.
- Business Wire•20 days ago
Phase I Clinical Trial Examines Safety of Using Cord Blood Stem Cells for Treating Children with Autism Spectrum Disorder
Novel research results from Duke University’s Robertson Clinical and Translational Cell Therapy Program published today in the April issue of Stem Cells Translational Medicine indicate promising developments related to using a baby’s own cord blood stem cells to treat Autism Spectrum Disorder .
- Zacks•2 months ago
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PKI : Summary for PerkinElmer, Inc. Common Stock - Yahoo Finance
PerkinElmer, Inc. (PKI)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||58.03 - 59.03|
|52 Week Range||45.35 - 59.03|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||27.55|
|Dividend & Yield||0.28 (0.48%)|
|1y Target Est||N/A|